Article

Analysis of IFT74 as a candidate gene for chromosome 9p-linked ALS-FTD

Laboratory of Neurogenetics, National Institute of Aging, NIH, Bethesda, MD, USA. <>
BMC Neurology (Impact Factor: 2.49). 02/2006; 6(1):44. DOI: 10.1186/1471-2377-6-44
Source: PubMed

ABSTRACT A new locus for amyotrophic lateral sclerosis--frontotemporal dementia (ALS-FTD) has recently been ascribed to chromosome 9p.
We identified chromosome 9p segregating haplotypes within two families with ALS-FTD (F476 and F2) and undertook mutational screening of candidate genes within this locus.
Candidate gene sequencing at this locus revealed the presence of a disease segregating stop mutation (Q342X) in the intraflagellar transport 74 (IFT74) gene in family 476 (F476), but no mutation was detected within IFT74 in family 2 (F2). While neither family was sufficiently informative to definitively implicate or exclude IFT74 mutations as a cause of chromosome 9-linked ALS-FTD, the nature of the mutation observed within F476 (predicted to truncate the protein by 258 amino acids) led us to sequence the open reading frame of this gene in a large number of ALS and FTD cases (n = 420). An additional sequence variant (G58D) was found in a case of sporadic semantic dementia. I55L sequence variants were found in three other unrelated affected individuals, but this was also found in a single individual among 800 Human Diversity Gene Panel samples.
Confirmation of the pathogenicity of IFT74 sequence variants will require screening of other chromosome 9p-linked families.

Download full-text

Full-text

Available from: Mark Cookson, Sep 02, 2015
0 Followers
 · 
212 Views
 · 
73 Downloads
  • Source
    • "However, a number of families have been reported with an autosomal dominant pattern of disease in which affected members may develop either FTD or ALS or both (FTD–ALS). Several of these families have shown genetic linkage to a region on chromosome 9p21, with the combined data defining a minimum linkage region of 3.7 Mb, containing only five known genes (Momeni et al., 2006; Morita et al., 2006; Vance et al., 2006; Valdmanis et al., 2007; Luty et al., 2008; Le Ber et al., 2009; Gijselinck et al., 2010; Boxer et al., 2011; Pearson et al., 2011). Importantly, the same chromosomal region has been identified in several large independent genome-wide association studies of both ALS and FTD, implicating the genetic defect at chromosome 9p in sporadic forms of both diseases (van Es et al., 2009; Laaksovirta et al., 2010; Shatunov et al., 2010; van Deerlin et al., 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Frontotemporal dementia and amyotrophic lateral sclerosis are closely related clinical syndromes with overlapping molecular pathogenesis. Several families have been reported with members affected by frontotemporal dementia, amyotrophic lateral sclerosis or both, which show genetic linkage to a region on chromosome 9p21. Recently, two studies identified the FTD/ALS gene defect on chromosome 9p as an expanded GGGGCC hexanucleotide repeat in a non-coding region of the chromosome 9 open reading frame 72 gene (C9ORF72). In the present study, we provide detailed analysis of the clinical features and neuropathology for 16 unrelated families with frontotemporal dementia caused by the C9ORF72 mutation. All had an autosomal dominant pattern of inheritance. Eight families had a combination of frontotemporal dementia and amyotrophic lateral sclerosis while the other eight had a pure frontotemporal dementia phenotype. Clinical information was available for 30 affected members of the 16 families. There was wide variation in age of onset (mean = 54.3, range = 34-74 years) and disease duration (mean = 5.3, range = 1-16 years). Early diagnoses included behavioural variant frontotemporal dementia (n = 15), progressive non-fluent aphasia (n = 5), amyotrophic lateral sclerosis (n = 9) and progressive non-fluent aphasia-amyotrophic lateral sclerosis (n = 1). Heterogeneity in clinical presentation was also common within families. However, there was a tendency for the phenotypes to converge with disease progression; seven subjects had final clinical diagnoses of both frontotemporal dementia and amyotrophic lateral sclerosis and all of those with an initial progressive non-fluent aphasia diagnosis subsequently developed significant behavioural abnormalities. Twenty-one affected family members came to autopsy and all were found to have transactive response DNA binding protein with M(r) 43 kD (TDP-43) pathology in a wide neuroanatomical distribution. All had involvement of the extramotor neocortex and hippocampus (frontotemporal lobar degeneration-TDP) and all but one case (clinically pure frontotemporal dementia) had involvement of lower motor neurons, characteristic of amyotrophic lateral sclerosis. In addition, a consistent and relatively specific pathological finding was the presence of neuronal inclusions in the cerebellar cortex that were ubiquitin/p62-positive but TDP-43-negative. Our findings indicate that the C9ORF72 mutation is a major cause of familial frontotemporal dementia with TDP-43 pathology, that likely accounts for the majority of families with combined frontotemporal dementia/amyotrophic lateral sclerosis presentation, and further support the concept that frontotemporal dementia and amyotrophic lateral sclerosis represent a clinicopathological spectrum of disease with overlapping molecular pathogenesis.
    Brain 03/2012; 135(Pt 3):709-22. DOI:10.1093/brain/awr354 · 10.23 Impact Factor
    • "Sequencing analysis of several genes mapped to 9p locus detected the presence of a disease segregating truncation mutation (Q342X) in the intra-flagellar transport protein 74(IFT74) in one independent American family with FTD-ALS.[65] However, no causal IFT74 mutations were identified in conclusively linked FTD-ALS families indicating additional loci (other than VCP and IFT74) for 9p linked FTD-ALS families. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Frontotemporal lobar degeneration (FTLD) is a highly heterogenous group of progressive neurodegenerative disorders characterized by atrophy of prefrontal and anterior temporal cortices. Recently, the research in the field of FTLD has gained increased attention due to the clinical, neuropathological, and genetic heterogeneity and has increased our understanding of the disease pathogenesis. FTLD is a genetically complex disorder. It has a strong genetic basis and 50% of patients show a positive family history for FTLD. Linkage studies have revealed seven chromosomal loci and a number of genes including MAPT, PGRN, VCP, and CHMB-2B are associated with the disease. Neuropathologically, FTLD is classified into tauopathies and ubiquitinopathies. The vast majority of FTLD cases are characterized by pathological accumulation of tau or TDP-43 positive inclusions, each as an outcome of mutations in MAPT or PGRN, respectively. Identification of novel proteins involved in the pathophysiology of the disease, such as progranulin and TDP-43, may prove to be excellent biomarkers of disease progression and thereby lead to the development of better therapeutic options through pharmacogenomics. However, much more dissections into the causative pathways are needed to get a full picture of the etiology. Over the past decade, advances in research on the genetics of FTLD have revealed many pathogenic mutations leading to different clinical manifestations of the disease. This review discusses the current concepts and recent advances in our understanding of the genetics of FTLD.
    Annals of Indian Academy of Neurology 12/2010; 13(Suppl 2):S55-62. DOI:10.4103/0972-2327.74246 · 0.51 Impact Factor
  • Source
    • "Another group of diseases that manifest impaired autophagic flux are due to mutations in the ESCRT complex machinery, which has been implicated in neurodegenerative disorders, such as frontotemporal dementia linked to chromosome 3 (FTD3) [47] and amyotrophic lateral sclerosis (ALS) [48,49]. Expression of a deletion mutant of CHMP2B, a subunit of the ESCRT-III complex, in cell and fly models, increased LC3-II levels and caused an accumulation of autophagosomes [50]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A large group of diseases, termed protein misfolding disorders, share the common feature of the accumulation of misfolded proteins. The possibility of a common mechanism underlying either the pathogenesis or therapy for these diseases is appealing. Thus, there is great interest in the role of protein degradation via autophagy in such conditions where the protein is found in the cytoplasm. Here we review the growing evidence supporting a role for autophagic dysregulation as a contributing factor to protein accumulation and cellular toxicity in certain protein misfolding disorders and discuss the available evidence that upregulation of autophagy may be a valuable therapeutic strategy.
    Current opinion in cell biology 11/2010; 23(2):190-7. DOI:10.1016/j.ceb.2010.10.010 · 8.74 Impact Factor
Show more